KalVista Posts First EKTERLY Revenue, Losses Widen Amid Launch Costs

TL;DR

**KalVista's EKTERLY launch is a double-edged sword: revenue is finally here, but ballooning commercialization costs mean more red ink for now, so watch for sales traction.**

AI Summary

KalVista Pharmaceuticals, Inc. reported its first product revenue of $13.692 million for the three and nine months ended September 30, 2025, following the FDA approval of EKTERLY (sebetralstat) on July 3, 2025, for hereditary angioedema (HAE). Despite this new revenue stream, the company's net loss widened to $49.482 million for the three months ended September 30, 2025, compared to $39.084 million in the prior year period, and to $158.914 million for the nine months ended September 30, 2025, up from $122.529 million. This increased loss is primarily due to a significant rise in selling, general and administrative expenses, which surged to $46.517 million for the quarter from $24.800 million, and to $125.997 million for the nine months from $63.511 million, reflecting commercialization efforts for EKTERLY. Research and development expenses decreased to $11.993 million for the quarter from $18.680 million. The company's cash and cash equivalents increased to $243.497 million as of September 30, 2025, from $182.326 million at December 31, 2024, bolstered by $139.438 million from convertible notes and $21.259 million from a royalty agreement. KalVista anticipates continued losses due to global commercialization and further development of EKTERLY, but expects sufficient funding for at least the next twelve months.

Why It Matters

KalVista's successful FDA approval and initial commercial sales of EKTERLY mark a pivotal shift from a pure R&D company to a commercial-stage biopharmaceutical firm, offering a new oral treatment option for HAE patients who previously relied on intravenous or subcutaneous methods. This could significantly disrupt the HAE treatment market, currently dominated by injectable therapies, and provides a competitive edge for KalVista. For investors, the immediate widening of net losses, driven by substantial selling, general, and administrative expenses, indicates the high cost of market entry and commercialization, which will test the company's ability to achieve profitability. Employees will see increased focus on sales and marketing, while customers gain a more convenient treatment. The broader market will watch to see if EKTERLY's convenience translates into significant market share against established competitors.

Risk Assessment

Risk Level: medium — The company has incurred operating losses since inception, with an accumulated deficit of $739.1 million as of September 30, 2025. While EKTERLY's approval and initial sales are positive, the net loss for the nine months ended September 30, 2025, increased to $158.914 million from $122.529 million in the prior year, driven by a 98% increase in selling, general and administrative expenses to $125.997 million, indicating significant commercialization costs.

Analyst Insight

Investors should monitor EKTERLY's sales growth in upcoming quarters to assess if the substantial commercialization expenses are translating into meaningful market penetration and revenue acceleration. Given the anticipated continued losses, a long-term perspective is required, focusing on the company's ability to manage its cash burn and achieve profitability as EKTERLY gains traction.

Financial Highlights

debt To Equity

N/A

revenue

$13.692M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$49.482M

eps

N/A

gross Margin

N/A

cash Position

$243.497M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $13.692M — Product revenue, net (First-time revenue for the three and nine months ended September 30, 2025)
• $49.482M — Net loss (3 months) (Increased from $39.084 million in Q3 2024)
• $158.914M — Net loss (9 months) (Increased from $122.529 million in the prior year period)
• $46.517M — Selling, general and administrative expenses (3 months) (Increased from $24.800 million in Q3 2024, reflecting commercialization efforts)
• $125.997M — Selling, general and administrative expenses (9 months) (Increased from $63.511 million in the prior year period, reflecting commercialization efforts)
• $243.497M — Cash and cash equivalents (As of September 30, 2025, up from $182.326 million at December 31, 2024)
• $139.438M — Proceeds from convertible notes (Received during the nine months ended September 30, 2025)
• $21.259M — Proceeds from royalty agreement (Received during the nine months ended September 30, 2025)
• $739.098M — Accumulated deficit (As of September 30, 2025, indicating historical losses)
• 50,546,293 — Shares outstanding (As of November 3, 2025)

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — registrant
• EKTERLY (company) — approved drug for HAE
• U.S. Food and Drug Administration (regulator) — approved EKTERLY on July 3, 2025
• TD Securities (USA) LLC (company) — sales agreement partner
• U.S. Bank Trust Company, National Association (company) — trustee for convertible notes
• New England Journal of Medicine (other) — publication for KONFIDENT clinical trial data
• Nasdaq Global Market (other) — exchange where common stock is registered
• Hereditary Angioedema (other) — disease treated by EKTERLY
• September 30, 2025 (date) — end of reporting period
• December 31, 2025 (date) — new fiscal year end

FAQ

Risk Factors

• FDA Approval and Commercialization Risks [high — regulatory]: The company's success is heavily reliant on the continued market acceptance and commercial viability of EKTERLY. Post-approval, risks include market penetration, competition, and potential regulatory actions that could impact sales or require further disclosures.
• Sustained Net Losses [high — financial]: KalVista reported a net loss of $49.482 million for Q3 2025, an increase from $39.084 million in Q3 2024. The nine-month loss widened to $158.914 million from $122.529 million. This trend is expected to continue due to global commercialization and development efforts.
• Increased SG&A Expenses [high — financial]: Selling, general, and administrative expenses surged to $46.517 million for Q3 2025 from $24.800 million in Q3 2024, and to $125.997 million for the nine months from $63.511 million. This reflects significant investment in commercialization activities for EKTERLY.
• Dependence on EKTERLY [high — operational]: The company's financial performance and future prospects are overwhelmingly dependent on the success of EKTERLY. Any setbacks in its market adoption, manufacturing, or regulatory standing could have a material adverse effect.
• Cash Burn Rate [medium — financial]: Despite an increase in cash to $243.497 million, the company anticipates continued losses, implying a substantial ongoing cash burn rate. While management expects sufficient funding for at least 12 months, future financing needs are a consideration.
• Future Development and Regulatory Hurdles [medium — regulatory]: Continued development of EKTERLY and potential future pipeline products will require significant R&D investment and navigation of complex regulatory pathways. Delays or failures in these areas pose a risk.
• Competitive Landscape [medium — market]: The HAE market may attract new entrants or existing competitors may enhance their offerings, impacting EKTERLY's market share and pricing power. The company needs to effectively differentiate its product.
• Dilution Risk from Financing [low — financial]: While convertible notes provided significant funding ($139.438 million), future financing needs, especially if losses continue or accelerate, could lead to equity dilution for existing shareholders.

Industry Context

The biopharmaceutical industry, particularly in rare diseases like Hereditary Angioedema (HAE), is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on breakthrough therapies to achieve market success. The HAE market is competitive, with established treatments and emerging therapies vying for patient and physician adoption.

Regulatory Implications

The FDA approval of EKTERLY is a critical milestone, but ongoing regulatory compliance and potential post-market surveillance are essential. Any adverse events or manufacturing issues could trigger regulatory scrutiny, impacting sales and reputation. The company must also navigate international regulatory pathways for global commercialization.

What Investors Should Do

1. Monitor SG&A expense trends closely to assess the efficiency of commercialization efforts for EKTERLY.
2. Evaluate the rate of EKTERLY adoption and market share gains against competitors to gauge revenue growth sustainability.
3. Assess the company's cash burn rate and runway, considering the need for potential future financing rounds.
4. Track R&D pipeline progress for any updates on future product development, which will be crucial for long-term growth beyond EKTERLY.

Key Dates

• 2025-07-03: FDA Approval of EKTERLY (sebetralstat) — Marks the company's first product approval and the commencement of its commercialization phase, enabling product revenue generation.
• 2025-09-30: End of Q3 2025 — Reporting period for the first product revenue and increased net loss due to commercialization expenses.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of cash and cash equivalents, showing an increase by Q3 2025.
• 2025-11-03: Date of Share Outstanding Disclosure — Provides context for per-share metrics and market capitalization calculations.

Glossary

EKTERLY (sebetralstat)

KalVista's first FDA-approved product for the treatment of hereditary angioedema (HAE). (The primary driver of current revenue and future growth expectations for the company.)

Hereditary Angioedema (HAE)

A rare genetic disorder characterized by recurrent episodes of severe swelling. (The specific disease indication for which EKTERLY is approved, defining the company's target market.)

Selling, General and Administrative (SG&A) Expenses

Costs incurred by a company for marketing, advertising, sales, and administrative functions, excluding R&D. (A significant driver of the increased net loss, reflecting the company's investment in launching and commercializing EKTERLY.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, representing the excess of expenses over revenues over time. (Indicates the company's historical unprofitability, a common characteristic of early-stage biopharmaceutical companies investing heavily in R&D and commercialization.)

Convertible Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity under certain conditions. (A source of significant funding ($139.438 million) that bolstered the company's cash position, but carries potential for future dilution.)

Year-Over-Year Comparison

Compared to the prior year period, KalVista has transitioned from a pre-revenue to a revenue-generating company with the launch of EKTERLY, reporting $13.692 million in product revenue for Q3 2025. However, this revenue has not yet offset the significant increase in SG&A expenses, leading to a wider net loss ($49.482 million vs. $39.084 million in Q3 2024). The company's cash position has improved substantially due to financing activities, but the overall financial picture reflects the high costs associated with commercializing a new drug.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq

Filing Documents

• kalv-20250930.htm (10-Q) — 1817KB
• kalv-ex4_1.htm (EX-4.1) — 1071KB
• kalv-ex10_1.htm (EX-10.1) — 44KB
• kalv-ex10_2.htm (EX-10.2) — 59KB
• kalv-ex31_1.htm (EX-31.1) — 19KB
• kalv-ex31_2.htm (EX-31.2) — 17KB
• kalv-ex32_1.htm (EX-32.1) — 12KB
• 0001193125-25-274442.txt ( ) — 8115KB
• kalv-20250930.xsd (EX-101.SCH) — 1013KB
• kalv-20250930_htm.xml (XML) — 981KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

F i nancial Statements

Item 1. F i nancial Statements KalVista Pharmaceuticals, Inc. Condensed Consolidated Ba lance Sheets (in thousands, except share and per share amounts) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 243,497 $ 182,326 Marketable securities 65,661 86,019 Accounts receivable, net 5,779 — Inventory 458 — Research and development tax credit receivable 1,343 11,417 Prepaid expenses and other current assets 8,488 6,217 Total current assets 325,226 285,979 Property and equipment, net 3,190 1,884 Right of use assets 9,096 5,574 Other assets 2,419 1,379 Total assets $ 339,931 $ 294,816 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 8,074 $ 5,726 Accrued expenses 20,767 18,936 Deferred revenue 11,512 — Lease liability - current portion 1,429 1,452 Royalty obligation - current portion 3,287 — Total current liabilities 45,069 26,114 Lease liability - net of current portion 9,128 4,437 Royalty obligation - net of current portion 129,707 99,906 Convertible notes 139,028 — Total liabilities 322,932 130,457 Stockholders' equity: Common stock, $ 0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 50,542,711 and 49,433,611 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 50 49 Additional paid-in capital 762,776 746,912 Accumulated deficit ( 739,098 ) ( 580,184 ) Accumulated other comprehensive loss ( 6,729 ) ( 2,418 ) Total stockholders' equity 16,999 164,359 Total liabilities and stockholders' equity $ 339,931 $ 294,816 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 KalVista Pharmaceuticals, Inc. Condensed Consolidated Statements of Opera tions and Comprehens

View Full Filing

View this 10-Q filing on SEC EDGAR